These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27872073)

  • 21. Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance.
    Chirakul S; Norris MH; Pagdepanichkit S; Somprasong N; Randall LB; Shirley JF; Borlee BR; Lomovskaya O; Tuanyok A; Schweizer HP
    Sci Rep; 2018 Jul; 8(1):10652. PubMed ID: 30006637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition.
    Tribuddharat C; Moore RA; Baker P; Woods DE
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2082-7. PubMed ID: 12821450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burkholderia ubonensis Meropenem Resistance: Insights into Distinct Properties of Class A β-Lactamases in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Bacteria.
    Somprasong N; Hall CM; Webb JR; Sahl JW; Wagner DM; Keim P; Currie BJ; Schweizer HP
    mBio; 2020 Apr; 11(2):. PubMed ID: 32291300
    [No Abstract]   [Full Text] [Related]  

  • 24. Examining the activity of cefepime-taniborbactam against
    Mojica MF; Zeiser ET; Becka SA; LiPuma JJ; Six DA; Moeck G; Papp-Wallace KM
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0049823. PubMed ID: 37768313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of bla(PenA) and bla(OXA) in Burkholderia pseudomallei Isolated from Patients at Sappasitthiprasong Hospital and Their Susceptibility to Ceftazidime and Carbapenems.
    Panya M; Thirat S; Wanram S; Panomket P; Nilsakul J
    J Med Assoc Thai; 2016 Jan; 99 Suppl 1():S12-6. PubMed ID: 26817233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multilocus sequence analysis, biofilm production, antibiotic susceptibility and synergy tests of Burkholderia species in patients with and without cystic fibrosis].
    Akışoğlu Ö; Engin D; Sarıçam S; Müştak HK; Şener B; Hasçelik G
    Mikrobiyol Bul; 2019 Jan; 53(1):22-36. PubMed ID: 30683036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
    Berrazeg M; Jeannot K; Ntsogo Enguéné VY; Broutin I; Loeffert S; Fournier D; Plésiat P
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6248-55. PubMed ID: 26248364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis.
    Levitt PS; Papp-Wallace KM; Taracila MA; Hujer AM; Winkler ML; Smith KM; Xu Y; Harris ME; Bonomo RA
    J Biol Chem; 2012 Sep; 287(38):31783-93. PubMed ID: 22843686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia.
    Sarovich DS; Price EP; Von Schulze AT; Cook JM; Mayo M; Watson LM; Richardson L; Seymour ML; Tuanyok A; Engelthaler DM; Pearson T; Peacock SJ; Currie BJ; Keim P; Wagner DM
    PLoS One; 2012; 7(2):e30789. PubMed ID: 22363490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of
    Schaumburg F; Idelevich EA; Mellmann A; Kahl BC
    Microb Drug Resist; 2022 May; 28(5):545-550. PubMed ID: 35512733
    [No Abstract]   [Full Text] [Related]  

  • 31. Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC beta-lactamase of a Serratia marcescens clinical isolate.
    Hidri N; Barnaud G; Decré D; Cerceau C; Lalande V; Petit JC; Labia R; Arlet G
    J Antimicrob Chemother; 2005 Apr; 55(4):496-9. PubMed ID: 15722393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resurrecting Old β-Lactams: Potent Inhibitory Activity of Temocillin against Multidrug-Resistant
    Zeiser ET; Becka SA; Barnes MD; Taracila MA; LiPuma JJ; Papp-Wallace KM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718248
    [No Abstract]   [Full Text] [Related]  

  • 33. Antibiotic Resistance Markers in Burkholderia pseudomallei Strain Bp1651 Identified by Genome Sequence Analysis.
    Bugrysheva JV; Sue D; Gee JE; Elrod MG; Hoffmaster AR; Randall LB; Chirakul S; Tuanyok A; Schweizer HP; Weigel LM
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396541
    [No Abstract]   [Full Text] [Related]  

  • 34. The Structural Role of N170 in Substrate-Assisted Deacylation in KPC-2 β-Lactamase.
    Parwana D; Gu J; Chen S; Bethel CR; Marshall E; Hujer AM; Bonomo RA; Haider S
    Angew Chem Int Ed Engl; 2024 Mar; 63(12):e202317315. PubMed ID: 38227422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of antibiotic resistance: several different amino acid substitutions in an active site loop alter the substrate profile of beta-lactamase.
    Palzkill T; Le QQ; Venkatachalam KV; LaRocco M; Ocera H
    Mol Microbiol; 1994 Apr; 12(2):217-29. PubMed ID: 8057847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Membrane-Bound PenA β-Lactamase of Burkholderia pseudomallei.
    Randall LB; Dobos K; Papp-Wallace KM; Bonomo RA; Schweizer HP
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1509-14. PubMed ID: 26711764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OXY-2-15, a novel variant showing increased ceftazidime hydrolytic activity.
    Nijhuis RH; Oueslati S; Zhou K; Bosboom RW; Rossen JW; Naas T
    J Antimicrob Chemother; 2015 May; 70(5):1429-33. PubMed ID: 25630648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis.
    Daccò V; Claut L; Piconi S; Castellazzi L; Garbarino F; Teri A; Colombo C
    Transpl Infect Dis; 2019 Jun; 21(3):e13082. PubMed ID: 30892778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal Evolution of the Pseudomonas-Derived Cephalosporinase (PDC) Structure and Activity in a Cystic Fibrosis Patient Treated with β-Lactams.
    Colque CA; Albarracín Orio AG; Tomatis PE; Dotta G; Moreno DM; Hedemann LG; Hickman RA; Sommer LM; Feliziani S; Moyano AJ; Bonomo RA; K Johansen H; Molin S; Vila AJ; Smania AM
    mBio; 2022 Oct; 13(5):e0166322. PubMed ID: 36073814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.